Cited 0 times in 
Cited 0 times in 
A Response to the Letter to the Editor: "Lazertinib Versus Osimertinib in EGFR-Mutant NSCLC: Efficacy, Toxicity, and Unaddressed Clinical Gaps
https://orcid.org/0000-0002-5562-270XItems in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.